Products
Platform
Research
Market
Learn
Compare PGIM India Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 2.37 | 1.87 |
NAV | ₹9.97 | ₹39.90 |
Fund Started | 19 Nov 2024 | 25 Jun 2018 |
Fund Size | ₹106.92 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹1000
₹100
Expense Ratio
2.37
1.87
NAV
₹9.97
₹39.90
Fund Started
19 Nov 2024
25 Jun 2018
Fund Size
₹106.92 Cr
₹6437.36 Cr
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | - | 5.80% |
3 Year | - | 26.90% |
5 Year | - | 19.51% |
1 Year
-
5.80%
3 Year
-
26.90%
5 Year
-
19.51%
Holding Analysis
Equity | 97.50% | 97.10% |
Cash | 1.02% | 2.90% |
Equity
97.50%
97.10%
Cash
1.02%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.89% |
Divi's Laboratories Ltd. | 9.82% |
Max Healthcare Institute Ltd. | 7.10% |
Aster DM Healthcare Ltd. | 6.35% |
Dr. Reddy's Laboratories Ltd. | 5.53% |
Mankind Pharma Ltd. | 4.76% |
JB Chemicals & Pharmaceuticals Ltd. | 4.53% |
Rubicon Research Ltd. | 3.87% |
Krishna Institute of Medical Sciences Ltd | 3.69% |
Ajanta Pharma Ltd. | 3.52% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Vivek Sharma | Dharmesh Kakkad |
Start Date | 11 Nov 2025 | 23 Feb 2021 |
Name
Vivek Sharma
Dharmesh Kakkad
Start Date
11 Nov 2025
23 Feb 2021
About Fund
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 19 Nov 2024 | 25 Jun 2018 |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
19 Nov 2024
25 Jun 2018